Is a
Clinical Study attributes
NCT Number
Trial Recruitment Size
480
Trial Sponsor
Clinical Trial Start Date
2006
0Primary Completion Date
2008
0Study Completion Date
2009
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Treatment0
Interventional Trial Phase
Phase 10
Participating Facility
Official Name
Phase 1 Study of CPX-351(Cytarabine:Daunorubicin) Liposome Injection in Patients With Advanced Hematologic Malignancies0
Last Updated
May 17, 2012
0Allocation Type
Non-Randomized0
Intervention Model
Single Group Assignment0
Masking Type
None (Open Label)0
Study summary
The primary objective of this study is to determine the recommended dose of CPX-351 for use in a phase 2 efficacy study in patients with leukemia. Secondarily, the study will assess the safety, serious adverse effects and how the body handles CPX-351. Preliminary evidence of antitumor activity will also be determined.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
